Drugs.com - Clinical Trials

Lilly to Offer All Approved Doses of Zepbound (tirzepatide) Single-Dose Vials Through LillyDirect Self Pay Pharmacy Solutions

INDIANAPOLIS, June 16, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced that the highest approved doses of Zepbound (tirzepatide)—12.5 mg and 15 mg—will soon be available in single-dose vials for $499 per month...

Jun 21, 2025 - 03:00
 0
Lilly to Offer All Approved Doses of Zepbound (tirzepatide) Single-Dose Vials Through LillyDirect Self Pay Pharmacy Solutions
INDIANAPOLIS, June 16, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced that the highest approved doses of Zepbound (tirzepatide)—12.5 mg and 15 mg—will soon be available in single-dose vials for $499 per month...
Read More

Tags:

Previous Article

Higher Dose of Wegovy Provided Average Weight Loss of 21% in People with Obesity...

Next Article

Celltrion Announces U.S. FDA Approval of Additional Presentation of Steqeyma (us...

Related Posts

Novo Nordisk Warns Consumers About Counterfeit Ozempic (semaglutide) Injection 1 mg in the US

Novo Nordisk Warns Consumers About Counterfeit Ozempic ...

May 12, 2025  0

Cellectar Granted U.S. FDA Breakthrough Therapy Designation for Iopofosine I 131 in Waldenstrom Macroglobulinemia (WM)

Cellectar Granted U.S. FDA Breakthrough Therapy Designa...

Jun 5, 2025  0

New Results for Johnson & Johnson’s Bleximenib Demonstrate Promising Antileukemic Activity in Combination with Venetoclax and Azacitidine for Acute Myeloid Leukemia

New Results for Johnson & Johnson’s Bleximenib Demonstr...

Jun 14, 2025  0